Does cog-4 have limited diagnostic test accuracy and validity for cognitive assessment in stroke survivors?
Our data suggest that many stroke survivors with MoCA-defined cognitive problems would not be detected by Cog-4. Subtest correlations suggest that Cog-4 may not be a valid measure of the cognitive domains that it purports to describe. Other brief cognitive screening tests may be better suited to acute stroke.
Frequent overexpression and gene amplification of EGFR and CCND1 make these molecules and their pathways potential therapeutic targets for ESCC. In addition, EGFR and CCND1 appeared to be independently altered suggesting alternative mechanisms for pathway activation. Therapeutic agents targeting these molecules are urged to be tested in clinical trials and comprehensive biological analyses should be included to properly interpret the outcome.